Limited efficacy for ibrutinib and venetoclax in T-prolymphocytic leukemia: results from a phase 2 international study

Affiliations

• ¹ Department of Internal Medicine I, University Hospital Cologne, Cologne, Germany.
• ² Department of Hematology, Cell Therapy, and Hemostaseology, University of Leipzig, Leipzig, Germany.
• ³ The Royal Marsden NHS Foundation Trust, London, United Kingdom.
• ⁴ UCO Ematologia, Azienda Sanitaria Universitaria Giuliano Isontina, Trieste, Italy.
• ⁵ DSM University of Trieste, Trieste, Italy.
• ⁶ Division of Hematology, Department of Medicine, Mayo Clinic, Rochester, MN.
• ⁷ Department of Hematology, University Medical Center Groningen, Groningen, The Netherlands.
• ⁸ Department of Clinical Haematology, Peter MacCallum Cancer Center, The Royal Melbourne Hospital and The University of Melbourne, Melbourne, Australia.
• ⁹ Department of Internal Medicine, Máxima Medical Center, Eindhoven, The Netherlands.
• ¹⁰ Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA.
• ¹¹ Oxford Cancer & Haematology Centre, Churchill Hospital, Oxford University Hospitals NHS Foundation Trust, Oxford, United Kingdom.
• ¹² Sorbonne Université, Assistance Publique-Hôpitaux de Paris, Service Hematologie Clinique, Hopital Pitie Salpetriere, Paris, France.
• ¹³ Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX.
• ¹⁴ Department of Global Medical Affairs, Oncology, AbbVie, North Chicago, IL.
• ¹⁵ Department of GSMD-Statistics, AbbVie, North Chicago, IL.
• ¹⁶ Department of CPPM Clinical PK/PD, AbbVie, North Chicago, IL.
• ¹⁷ Universitaetsklinik fuer Innere Medizin I, Klinische Abteilung fuer Haematologie und Haemostaseologie, Medizinische Universitaet Wien, Vienna, Austria.